162 related articles for article (PubMed ID: 36907365)
1. Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis.
Zhu Z; Shen G; Li J; Qiu T; Fang Q; Zheng Y; Xin Y; Liu Z; Zhao F; Ren D; Zhao J
Crit Rev Oncol Hematol; 2023 Apr; 184():103960. PubMed ID: 36907365
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review.
Abuhelwa Z; Alloghbi A; Alqahtani A; Nagasaka M
Drugs; 2022 Jun; 82(9):979-987. PubMed ID: 35759121
[TBL] [Abstract][Full Text] [Related]
3. Incidence of antibody-drug conjugate-related fatigue in patients with breast cancer: A systematic review and meta-analysis.
Zhang H; Shen G; Yang P; Li J; Li Z; Liu Z; Wang M; Zhao F; Ren D; Liu Z; Zhao J; Zhao Y
Crit Rev Oncol Hematol; 2024 Apr; 196():104292. PubMed ID: 38403093
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.
Nishino M; Giobbie-Hurder A; Hatabu H; Ramaiya NH; Hodi FS
JAMA Oncol; 2016 Dec; 2(12):1607-1616. PubMed ID: 27540850
[TBL] [Abstract][Full Text] [Related]
5. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.
Powell CA; Modi S; Iwata H; Takahashi S; Smit EF; Siena S; Chang DY; Macpherson E; Qin A; Singh J; Taitt C; Shire N; Camidge DR
ESMO Open; 2022 Aug; 7(4):100554. PubMed ID: 35963179
[TBL] [Abstract][Full Text] [Related]
6. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC.
Suh CH; Park HS; Kim KW; Pyo J; Hatabu H; Nishino M
Lung Cancer; 2018 Sep; 123():60-69. PubMed ID: 30089596
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
[TBL] [Abstract][Full Text] [Related]
9. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
Parisi C; Mahjoubi L; Gazzah A; Barlesi F
Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
[TBL] [Abstract][Full Text] [Related]
10. Incidence of HER2-targeted antibody-drug conjugates-related cardiac events: a meta-analysis.
Liu F; Li H; Yin G; Pan Y
J Cancer; 2024; 15(1):90-102. PubMed ID: 38164284
[No Abstract] [Full Text] [Related]
11. Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials.
Fu Z; Gao C; Xie J; Zhang C; Li S; Gu M; Shi C
BMC Cancer; 2023 Oct; 23(1):960. PubMed ID: 37817092
[TBL] [Abstract][Full Text] [Related]
12. Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO's pharmacovigilance database.
Ma Z; Zhang Y; Zhu M; Feng L; Zhang Y; An Z
Expert Rev Clin Pharmacol; 2022 Nov; 15(11):1351-1361. PubMed ID: 36111954
[TBL] [Abstract][Full Text] [Related]
13. Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis.
Li J; Shen G; Liu Z; Liu Y; Wang M; Zhao F; Ren D; Xie Q; Li Z; Liu Z; Zhao Y; Ma F; Liu X; Xu Z; Zhao J
Cancer Innov; 2023 Oct; 2(5):346-375. PubMed ID: 38090386
[TBL] [Abstract][Full Text] [Related]
14. The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: A systematic review and meta-analysis.
Suh CH; Kim KW; Pyo J; Hatabu H; Nishino M
Lung Cancer; 2019 Jun; 132():79-86. PubMed ID: 31097098
[TBL] [Abstract][Full Text] [Related]
15. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer.
Hackshaw MD; Danysh HE; Singh J; Ritchey ME; Ladner A; Taitt C; Camidge DR; Iwata H; Powell CA
Breast Cancer Res Treat; 2020 Aug; 183(1):23-39. PubMed ID: 32591987
[TBL] [Abstract][Full Text] [Related]
16. Treatment-related adverse events of antibody-drug conjugates in clinical trials: A systematic review and meta-analysis.
Zhu Y; Liu K; Wang K; Zhu H
Cancer; 2023 Jan; 129(2):283-295. PubMed ID: 36408673
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Pneumonitis Among Limited Stage Small Cell Lung Cancer Patients Exposed to Concurrent Chemoradiation: A Systematic Literature Review and Meta-Analysis.
Kuang Y; Singh R; Nevo A; Deitz AC; Pietanza MC; Liu A; Uyei J; Zu K
Clin Lung Cancer; 2022 Dec; 23(8):659-669. PubMed ID: 36266183
[TBL] [Abstract][Full Text] [Related]
19. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
Swain SM; Nishino M; Lancaster LH; Li BT; Nicholson AG; Bartholmai BJ; Naidoo J; Schumacher-Wulf E; Shitara K; Tsurutani J; Conte P; Kato T; Andre F; Powell CA
Cancer Treat Rev; 2022 May; 106():102378. PubMed ID: 35430509
[TBL] [Abstract][Full Text] [Related]
20. Effect of Sequence of Radiotherapy Combined With Immunotherapy on the Incidence of Pneumonitis in Patients With Lung Cancer: A Systematic Review and Network Meta-Analysis.
Mi S; Liang N; Zhang Y; Zhang Y; Wang F; Qiao L; Chen F; Hu P; Zhang J
Clin Lung Cancer; 2024 Jan; 25(1):18-28.e3. PubMed ID: 37612176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
